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Genetic aberrationsCastration-resistant prostate cancer (CRPC) is a lethal disease, and improvement with
androgen-deprivation therapy has plateaued. Next-generation sequencing studies have led to signiﬁcant
advances in our understanding of genomic alterations in prostate cancer. The most common genomic
aberrations in this malignancy are the transcription factor fusion of TMPRSS2–ETS, and mutations in
TP53, AR, RB1 and PTEN/PIK3CA. Some of these alterations are actionable by drugs available in the clinic.
In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are pre-
sent in both somatic and germline form in a signiﬁcant minority of prostate cancer; these abnormalities
can be targeted by drugs such as platinums and PARP inhibitors. In the era of tumour proﬁling, targeting
molecular alterations may provide an opportunity for new therapeutic approaches. Although there are
promising new agents to attack a variety of genomic signal abnormalities, biomarker-matched therapy
(other than for androgens) have been utilised in only 2.0% of clinical trials (September 2011 through
September 2014; https://clinicaltrials.gov) for prostate cancer. Enhanced efforts to deﬁne subsets of
patients with prostate cancer based on their molecular anomalies, and match them with cognate
therapies, warrant investigation.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer continues to be the most frequently occurring
cancer in men in the United States, and the second leading cause
of cancer-related deaths in men [1,2]. Although the 10-year
disease-speciﬁc survival rate of low-risk, localised prostate cancer
patients is more than 90%, the prognosis for the 10–20% of patients
who develop castration-resistant prostate cancer (CRPC) remains
poor [3,4]. Therefore, novel therapeutic approaches for prostate
cancer are needed.
There are 19 Food and Drug Administration (FDA)-approved
agents for prostate cancer (Table 1) [5–26]. The majority of these
agents (N = 9 (47%)) are hormonal modulators targeting the andro-
gen pathway. Gonadotropin-releasing agonists (goserelin acetate,
leuprolide acetate, histrelin acetate, or triptorelin pamoate), and
androgen-receptor blockers (ﬂutamide, and bicalutamide) were
approved by the FDA before 2000, and have been the backbone
of prostate cancer treatment [5–11]. However, advanced prostate
cancer ultimately develops resistance to androgen-deprivationtherapy. Newer agents, such as abiraterone and enzalutamide,
are effective in CRPC [16]. Abiraterone inhibits CYP17, a critical
enzyme in the synthesis of testosterone, and therefore decreases
androgen synthesis in adrenal glands, testes, and tumour cells
[12,13]. Enzalutamide is a newer androgen-receptor (AR) blocker,
which has greater afﬁnity for the receptor, and it inhibits the
nuclear translocation of the AR, DNA binding, and co-activator
[15]. Although abiraterone and enzalutamide showed survival ben-
eﬁt in castrate-resistant disease, prostate cancer cells eventually
develop resistance [13–15]. Therefore, androgen deprivation alone
is not sufﬁcient to control prostate cancer.
Phase III studies demonstrate survival beneﬁts with chemother-
apeutic agents (docetaxel and cabazitaxel) and improved quality of
life (mitoxantrone) [16–19]. However, their effectiveness is not
long lasting, and toxicity eventually becomes a challenge in the
prostate cancer patient population. Sipuleucel-T, a novel cancer
vaccine, was associated with prolonged overall survival compared
to that seen in a sham-treated control [25,26].
Bone-seeking radiopharmaceuticals use unique properties of
speciﬁc radioisotopes to target metastatic disease in the bone.
Strontium-89 and samarium-153 are beta particle emitters, and
they are effective in relieving bone-related symptoms; they do
not, however, improve survival [20,24]. Radium-223 was the ﬁrst
Table 1
FDA-approved agents for prostate cancer [5–26].
Class Name Year of FDA approval Mechanism of action Refs.
Hormonal agents Goserelin acetate 1989 GnRH agonist [5]
Leuprolide acetate 1989 GnRH agonist [6]
Histrelin acetate 1991 GnRH agonist [7]
Bicalutamide 1995 Androgen receptor blocker [8]
Flutamide 1989 Androgen receptor blocker [9]
Triptorelin pamoate 2000 GnRH agonist [10]
Degarelix 2008 GnRH antagonist [11]
Abiraterone 2011 CYP17 inhibitor [12,13]
Enzalutamide 2012 Androgen receptor blocker [14,15]
Chemotherapy Estramustine 1981 Microtubules inhibitor [16]
Mitoxantrone 1996 Alkylating agent and TOPOII inhibitor [17]
Docetaxel 2004 Microtubules inhibitor [17,18]
Cabazitaxel 2010 Microtubules inhibitor [17,19]
Bone-seeking radiopharmaceuticals Strontium-89 1993 Beta particle emitter [12,20]
Samarium-153 1997 Beta particle emitter [12,24]
Radium 223 2013 Alpha particle emitter [21,22]
Bone-directed agents Zoledronic acid 2002 Osteoclast inhibition [16,23]
Denosumab 2013 RANK ligand inhibitor [16,23]
Immunotherapy Sipuleucel-T 2010 Cancer vaccine [25,26]
Abbreviations: GnRH = gonadotropin-releasing hormone; RANK = receptor activator of nuclear factor kappa-B.
762 G. Khemlina et al. / Cancer Treatment Reviews 41 (2015) 761–766bone-seeking radioisotope that showed an overall survival beneﬁt
[21,22]. Other bone-directed agents, zoledronic acid and
denosumab, attenuated skeletal-related events [23].
Taken together, most of the progress in the past decade in pros-
tate cancer treatment has been made possible by the development
of newer androgen pathway-targeted therapy. As mentioned, nine
therapies that manipulate androgen levels have been approved for
prostate cancer (Table 1). These treatments are not without side
effects, including hot ﬂashes, fatigue, sexual dysfunction, and
osteoporosis [27]. Although there are well-known genomic
alternations in prostate cancer, molecular-targeted therapy for this
malignancy has not been extensively studied in the clinic. We
review the genomic landscape of prostate cancer and implications
for clinical research in this disease.
Genomic aberrations in prostate cancer
Prostate cancer shows biological heterogeneity, which likely
reﬂects underlying genomic diversity. The oncogenic landscape of
prostate cancer has become clearer after next-generation sequenc-
ing and microarray-based interrogation [28–33]. Common
genomic aberrations in prostate cancer include: transcription
factor fusion of TMPRSS2–ETS, and mutations and copy number
alterations of TP53, AR, RB1 and PTEN/PIK3CA, as well as alterations
in DNA repair genes such as BRCA2 and ATM (Table 2) [33–55].
TMPRSS2–ETS fusion
Transmembrane protease, serine 2 (TMPRSS2) is a serine
protease regulated by androgens [34–36,56]. ERG and ETV1 belong
to the ETS transcription factor family, and are fused with TMPRSS2
in approximately 50–79% cases of prostate cancer [28–32,36].
TMPRSS2–ETS fusion is associated with a poor prognosis in loca-
lised prostate cancer [57]. Recent preclinical studies have identi-
ﬁed targetable cofactors, such as PARP1, DNAPK, and HDAC1, and
inhibition of these cofactors has conferred preferential sensitivity
in ETS-positive malignancies in preclinical models [37,38,58]. A
number of phase I studies of PARP1, DNAPK, or HDAC1 inhibitors
have been done in patient populations including those with ERG
fusion-positive malignancies [38]. Ongoing phase II studies have
focused on the inhibition of PARP1 as a strategy to target ETSfusion-positive disease, including a randomized study with
veliparib, in which patients with prostate cancer are stratiﬁed
based on the fusion status of ETS (NCT01576172) [38]. Other
PARP1 inhibitors being assessed as monotherapy in CRPC include
olaparib (AZD-2281/KU-0059436; phase II, clinicaltrials.gov identi-
ﬁer NCT01682772) and niraparib (MK-4827; phase I expansion
cohort in prostate cancer, NCT00749502) [38].
TP53
Approximately 3–47% of prostate cancer specimens harbour
TP53 mutations, and 2–15% contain homozygous deletion
[28–31,33]. The tumour suppressor p53 plays a key role in main-
taining genomic stability and preventing tumourigenesis [59]. A
previous study demonstrated that the TP53R270H mutation was suf-
ﬁcient to induce prostate cancer in mice [60]. Mutation or deletion
of TP53was associatedwith increased risk of recurrence [61].Wee-1
inhibitors, such as MK-1775, can target TP53 mutated malignancy
[62]. The TP53 gene also regulates the expression of VEGF, and
anti-angiogenic agents, such as bevacizumab, were associated with
improved survival in patients harbouring TP53-mutant tumours, in
a retrospective study [41,63,64]. A phase III randomized trial com-
paring docetaxel/prednisone with or without bevacizumab in
CRPC patients found no difference in overall survival [65].
However, this study did not screen patients based on the TP53
mutation, and their TP53mutation status was not investigated.
Androgen receptor (AR)
From 2–18% of prostate cancer specimens harbour androgen
receptor (AR) mutations, and 5–52% demonstrate ampliﬁcation
[28–31,33]. Ampliﬁcation occurs rarely in untreated primary pros-
tate cancers, with the observed frequency between 0% and 5%
[66,67,69,70]. However, ampliﬁcation of the AR was found in 20–
52% of hormone-refractory prostate cancers [28–31,66–71]. The
AR belongs to the steroid hormone group of nuclear receptors
and acts as a ligand-dependent transcription factor that controls
the expression of speciﬁc genes. Prostate cancer initially responds
to androgen-deprivation therapy, but it eventually becomes
castration-resistant. The AR remains a key regulator in CRPC [42].
There are several proposed mechanisms of resistance. An AR
Table 2
Commonly aberrant genes in prostate adenocarcinoma [28–55].
Gene Aberration frequency
[28–36]
Pathway Function Examples of targeted agent
TMPRSS2–
ETS
Gene fusion: 50–79% Androgen receptor pathway,
epigenetic regulation, DNA
repair pathway
Plays a critical role in prostate cancer progression
by disrupting the AR lineage-speciﬁc differentiation
programme, and mediating invasion [35]; regulates
the epigenetic programme; interacts with PARP1
[37]
PARP1 inhibitors: veliparib
(NCT01576172)
Olaparib (AZD-2281/KU-0059436; phase
II, NCT01682772)
Niraparib (MK-4827; phase I expansion in
prostate cancer, NCT00749502) [38]
TP53 Mutation: 3–47%
Loss: 2–15%
P53 pathway Tumour suppressor and regulator of the expression
of target genes, inducing cell cycle arrest, apoptosis,
senescence, DNA repair [39]
MK-1775 (Wee-1 inhibitor) [40]
Patients with TP53 mutations may have
better outcomes with bevacizumab [41]
AR Mutation: 2–18%
Ampliﬁcation: 5–52%
(early-stage 0–5%,
castrate-resistant
20–52%)
Nuclear receptor
transcription pathway
Ligand-dependent transcription factor that controls
the expression of speciﬁc genes [42]
Abiraterone
Enzalutamide
Newer CYP17 inhibitor, such as CFG-920,
VT-464[43,44]
Newer anti-androgen, such as ODM-201,
AZD-3514 [43,44]
PTEN Mutation: 2–14%
Loss: 12–41%
PI3K pathway Tumour suppressor. Negative regulator of the
phosphatidylinositol-PI3K pathway [45]
mTOR inhibitor, everolimus [46]
PI3K inhibitor AZD8186 and AKT inhibitor
AZD5363 [47]
PIK3CA Mutation: 3–4%
Ampliﬁcation: 4–10%
PI3K pathway Responsible for coordinating a diverse range of cell
functions including proliferation, cell survival,
degranulation [39]
TORC1 inhibitor rapamycin and its
analogues: everolimus, temsirolimus, and
ridaforolimus [48–50]
RB1 Mutation: 1–14%
Loss: 5–23%
Cell cycle pathway Tumour suppressor
Key regulator of entry into cell division [39]
Azacitidine [51]
APC Mutation: 3–10% Wnt-signalling pathway Encodes a tumour suppressor protein that acts as an
antagonist of the Wnt signalling pathway [39]
CHD1 Mutation: 2–8%
Loss: 5–20%
Chromatin regulation
pathway
ATP-dependent chromatin-remodelling factor.
Regulates negatively DNA replication [39]
MYC Ampliﬁcation: 2–20% Cell cycle pathway Plays a role in cell cycle progression, apoptosis and
cellular transformation [39]
MYC and aurora kinase A (AURKA) co-
ampliﬁed prostate cancer was sensitive to
AURKA inhibitors in vitro and in vivo [91]
BRCA2 Mutation: 9%
Loss: 3%
DNA repair Germline mutation in 2–6% of patients [33] Confers sensitivity to platinums and PARP
inhibitors [33,53,54]
ATM Mutation: 5% DNA repair Germline mutation in 1% of patients [33] Confers sensitivity to platinums and PARP
inhibitors [33,55]
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[72]. An AR splice variant 7 (AR-V7) was associated with resistance
to abiraterone and enzalutamide with poor survival [73]. Another
study found that an AR splice variant and its ampliﬁcation status
appear to be able to determine whether sequencing AR-targeted
therapies was a feasible strategy [43].
In addition to approved AR-targeting therapy (Table 1), there
are multiple new AR-directed therapies in early stages of clinical
development including: (i) CFG-920, a nonsteroidal CYP17 inhibi-
tor; (ii) VT-464, a nonsteroidal selective inhibitor of 17,20-lyase;
(iii) ODM-201, an anti-androgen; (iv) AZD-3514, a small molecule
that inhibits nuclear translocation of the AR and down-regulates of
its expression; (v) ARN-509, a competitive AR inhibitor that is fully
antagonistic to AR overexpression [43,44,74]; (vi) EPI-001, a small
molecule that is antagonistic to the amino-terminus of the AR [75],
and Galentinon, a dual androgen receptor blocker and CYP17 inhi-
bitor, which may have effects in patients with AR-V7 variant
(NCT01709734 and NCT02438007) [76].
The PTEN/PI3K/AKT/mTOR pathway
The signalling pathway involving PTEN, PI3K and AKT plays a
central role in the regulation of cell growth and death [77]. The
PI3K/AKT/mTOR pathway is fundamental to the metastatic poten-
tial of prostate cancer, providing a strong rationale for targeting the
PI3K/AKT/mTOR pathway in this disease [46]. Supporting the view
that PTEN and PIK3CA genes act in the same signalling pathway,genetic alterations of these genes in prostate cancer were largely
mutually exclusive [77].
Approximately 2–14% of prostate cancer specimens harbour
PTEN mutations, and 12–41% have copy number loss [28–31,33].
Mutations in PIK3CA were observed in 3–4% of patients, and
ampliﬁcations were reported in 4–10% of cases. The PTEN gene
is a negative regulator of the PI3K/AKT signalling pathway [45].
A combination of PTEN and TP53 deﬁciency in prostate cancer
cells synergistically leads to robustly elevated hexokinase 2
expression, which fuels aggressive prostate cancer growth in vivo
[78]. The loss of PTEN was found to be associated with a poor
prognosis [79].
Dysregulation of the PI3K pathway due to PTEN or PIK3CA aber-
rations can conceivably be targeted by mTOR inhibitors, such as
everolimus. Everolimus demonstrated PSA response in 11% of
patients with CRPC in a non-biomarker selected population [48].
The PSA response to everolimus was correlated with a PTEN dele-
tion by FISH [48]. Everolimus was safely combined with bicalu-
tamide and docetaxel [80,81]. Novel inhibitors are under
development, for examples: AKT inhibitor AZD5363, and a
PI3Kb/d inhibitor AZD8186 [47]. Both agents showed potent
anti-tumour activity in multiple prostate cancer preclinical mod-
els, and they were equally effective in vivo in a PTEN-deleted model
[47]. In addition, targeting of the AKT and androgen receptor path-
ways with AZD5363 and enzalutamide signiﬁcantly delayed the
development of enzalutamide-resistant prostate cancer in preclin-
ical models [82].
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Approximately 1–14% of prostate cancer specimens harbour
RB1 mutations, and 5–23% of prostate cancers demonstrated loss
of RB1 [28–31,33]. The RB1 gene is a tumour suppressor, and
impairment of RB function is sufﬁcient to upregulate the androgen
receptor output and confer castration resistance [83]. The RB1 gene
is frequently deleted and methylated in CRPC, which points to a
possible therapeutic option with hypomethylating agents, such
as 5-azacytidine [51]. Azacytidine resulted in some PSA reduction
in a phase II study of non-biomarker-selected CRPC [84]. Also, an
animal study demonstrated higher sensitivity to cabazitaxel in
CRPC tumour with loss of RB [85].
APC
From 3–10% percent of prostate cancer specimens harbour APC
mutations [28–31,33]. The APC gene encodes a tumour suppressor
protein, which acts as an antagonist of theWnt signalling pathway.
It is also involved in other processes, including cell migration and
adhesion, transcriptional activation, and apoptosis [39]. A
high-level of APC promoter methylation was shown to be an
independent predictor of a poor prognosis in prostate cancer
[86]. Wnt inhibitors are in clinical development.
CHD1
Approximately 2–8% of prostate cancer specimens harbour
CHD1 mutations, and 5–20% contain deletions [28–31,33]. CHD1
genes alter gene expression, possibly by modiﬁcation of chromatin
structure, thus altering access of the transcriptional apparatus [39].
A focal deletion or mutation of CHD1 (CHD1) was identiﬁed that
was signiﬁcantly associated with the fusion-negative (ETS) status
of the ETS gene family [29]. The CHD1 deletion may be responsible
for cell invasiveness in a subset of prostate cancer and play a
possible novel role in altered chromatin remodelling in prostate
tumourigenesis [87]. Currently, there is no targeted therapy for
CHD1 aberrations.
MYC
Approximately 2–20% of prostate cancer specimens exhibitMYC
ampliﬁcation [28–31,33]. The protein encoded by MYC is
multi-functional, and plays a role in cell cycle progression, apopto-
sis and cellular transformation [39]. The MYC gene has previously
been validated as a driver of prostate cancer [88,89]. Targeting of
MYC could be a critical strategy against PTEN-deﬁcient prostate
cancer [90]. Co-ampliﬁcation of MYC and aurora kinase A
(AURKA) resulted in sensitivity to aurora kinase inhibitors in vitro
and in vivo, thereby providing a rationale for trials of this molecular
and histologic subset [52,91].
DNA repair genes
Aberrations in DNA repair genes such as BRCA2 and ATM have
been recently shown to be present in both somatic and germline
form in a signiﬁcant minority of prostate cancers [33,39,92]
(Table 2). These aberrations can be targeted by platinums and
PARP inhibitors [53–55].
BRCA2
Approximately 9% of prostate cancer specimens exhibit BRCA2
mutations, including 2–6% pathogenic germline BRCA2 mutations
[33,92]. Biallelic loss was observed in 3% of patients [33]. BRCA2
is involved in maintenance of genome stability, speciﬁcally the
homologous recombination pathway for double-strand DNA repair[39]. BRCA2 germline mutations not only confer a high risk of pros-
tate cancer, but are also an independent prognostic factor for
cause-speciﬁc survival in all stages of prostate cancer including
localised disease [93,94].
CRPC affected individuals with biallelic BRCA2 loss experienced
clinical beneﬁt from poly(-ADP-ribose) polymerase (PARP) inhibi-
tion, providing evidence of clinical actionability [33,53,54].
ATM
Approximately 5% of prostate cancer specimens exhibit somatic
ATM alterations including some 1% of pathogenic germline muta-
tions [33]. ATM acts a controller of cell cycle checkpoint signalling
pathways that are required for cell response to DNA damage and
for genome stability [39]. ATM has been reported to be highly acti-
vated in prostatic intraneoplasia and somemissense variants of the
ATM gene confer a moderate increased risk of prostate cancer [95],
ATM mutations were observed in affected individuals who
achieved clinical responses to PARP inhibition and predicted to
beneﬁt from this therapy [33,55].Clinical trials for prostate cancer
A search of clinicaltrials.gov for new prostate cancer protocols
registered during the past 3 years identiﬁed 761 protocols (search
criteria: search term = prostate cancer; study type = interven-
tional; ﬁrst received = from 09/01/2011 to 09/01/2014) [96]. The
761 protocol summaries were manually reviewed, and protocols
for radiation, procedure, imaging, diagnostic tests, prevention,
and life style modiﬁcation interventions were excluded. The drug
interventional studies total 357. Of these 357 protocols, only 5
(2.0%) used selective inclusion criteria to identify a subset of
patients based upon laboratory molecular/biomarker data and
treatment with a cognate therapy that was believed to impact or
biologically match the biomarker. There were 73 (20.4% of 357)
targeted therapy trials, but these trials did not use biomarker or
genomic alterations for screening patients. The remainder of the
studies were: hormonal therapy (123 trials, 34.5%), chemotherapy
(48 trials, 13.4%), immunotherapy/vaccine trials (52 trials, 14.6%),
and others such as radium-223, or statins (54 trials, 15.1%).
These results suggest that there is still a remarkable paucity of tri-
als addressing molecular/biomarker stratiﬁcation in prostate
cancer.Conclusions
Despite the progress in the past decades, prostate cancer
remains a major cause of death in the U.S. Pharmaceutical research
has emphasised AR modulation, and 9 agents approved by the FDA
for prostate cancer target the AR pathway. Multiple newer
AR-modulating agents are in development. These drugs are not
without side effects including impotence, hot ﬂashes, osteoporosis,
fatigue, loss of muscle mass and anemia [97]. Recent studies have
also suggested multiple escape mechanisms that lead to renewed
AR signalling under castration levels of androgens [13,98,99].
Therefore, understanding the molecular mechanisms leading to
CRPC and identifying alternative targets are important to identify
more effective treatments for CRPC [100].
In other tumour types such as BRAF-mutant melanoma [101],
and EGFR- or ALK-aberrant non-small cell lung cancer [102–104],
signiﬁcant improvements have been achieved by matching tar-
geted agents to tumours harbouring the cognate molecular abnor-
mality. Several theoretically ‘actionable’ aberrations exist in
prostate cancer, including PTEN, and PIK3CA. Indeed, aberrations
in the PI3K/AKT/mTOR pathway have been discerned in a substan-
tial subset of patients with prostate cancer. These aberrations can
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and ATM are also altered in prostate cancer (with a subset of
patients having germline mutations). PARP inhibitors and plat-
inums can effectively target these abnormalities in several cancers,
and merit further exploration in BRCA2- and ATM-aberrant prostate
cancer [33,105]. Despite the number of aberrations that can be tar-
geted, relatively few have been addressed in clinical trials of pros-
tate cancer, with only 2.0% of clinical trials (posted on
clinicaltrials.gov in the last 3 years; September 1, 2011, through
September 1, 2014) employing a biomarker-based patient selec-
tion strategy. Efforts to target biomarker-deﬁned subsets of
patients with prostate cancer and to expand current research
beyond androgen inhibition is needed.
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